ОЦЕНКА АНТИГИПЕРТЕНЗИВНОЙ ЭФФЕКТИВНОСТИ ЭНАЛАПРИЛА У ЖЕНЩИН В ПОСТМЕНОПАУЗЕ С ИСПОЛЬЗОВАНИЕМ АМБУЛАТОРНЫХ МЕТОДОВ ИЗМЕРЕНИЯ АРТЕРИАЛЬНОГО ДАВЛЕНИЯ

1. Shalnova S.A., Deev A.D., Oganov R. Arterial hypertension impact on mortality in Russia. // European Heart J. 1998. V. 19. P. 106.

2. Matthews K.A,Meilahn E., Kuller L.H. et. al. Menopause and risk factors for coronary heart disease//N. Engl. J. Med. 1989;321:641-646.

3. Prusse D.I., Stimpel M. Blood pressure response and safety profile of moexipril and nitredipine in postmenopausal women//Hypertens. 1997; 29: 844.

4. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial Hypertension//Hypertens 2003;21: 1011-1059.

5. Zuther P., Witte K., Lemmer B. ABPM-FIT and CV-SORT: an easy-to-use software package for detailed analysis of data from ambulatory blood pressure monitoring//Blood Press Monit. 1996;1: 347-354.

6. AsmarR., ZanchettiA. Guidelines for the use of self blood pressure monitoring: a summary report of the first international consensus conference//J.Hypertens. 2000; 18: 493-508.

7. Mancia G. et. al. An ambulatory blood pressure monitoring of the comparative efficacy of two angiotensin II receptor antagonists, irbesartan and valsartan//Blood Press Monit 2002, 7:135-142.

8. Kario K. Early morning risk management in hypertension//CMG 2005;68 pp.

9. Hansson L. et. al., for the NORDIL Study Group: Randomized trial of effects of calcium antagonist compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem study//Lancet 2000; 356-365.

10. Pepine C.J., Handberg E.M. et. al. for the INVEST investigators: A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil -Tradolapril Study (INVEST): arandomized controlled trial//JAMA 2003;290:2805-2819.

11. Zanchetti A., Safar M., Rizzoni D. et al. on behalf of the ELSA investigators: Calcium antagonist lacipidine slows down progression of asymptomatic carotid atherosclerosis. Principal result of European Lacipidine Study on Atherosclerosis.(ELSA), a randomized., double-blind, long-term trial//Circulation 2002; 106: r47-r52.

12. The ALLHAT Officers and Coordinators for The ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)// JAMA 2002;288:2981-2997. 13. Hansson L. et. al. for the STOP-Hypertension-2 study group: Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in Swedish Trial in Old Patients with Hypertension -2 study // Lancet 1999; 354: 1751-1756.

13. Staessen J., Ginocchio G., Thijs L. et. al. Conventional and ambulatory blood pressure and menopause in a prospective population study//J. Hum. Hypertens. 1997;11:507-514.

14. Pickering T.G., Hall J.E., Appel L.J., et. al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Part 1: Blood Pressure Measurement in Humans. A Statement for Professional and Public Education of the American Heart Association Council on High Blood Pressure Research//Circulation. 2005; 111:697-716.